587879-32-1
Chemical Structure
P552-02
- CAS No.: 587879-32-1
- Formula:C19H26ClN7O4
- Molecular Weight:451.91
IUPAC Name: 3,5-diamino-6-chloro-N-(N-(4-(4-(2,3-dihydroxypropoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide
InChIKey: NTRKMGDUWYBLMS-UHFFFAOYSA-N
SMILES: O=C(NC(=N)NCCCCC1=CC=C(OCC(O)CO)C=C1)C2=NC(Cl)=C(N=C2N)N
Biological Activity: P552-02 is an epithelial sodium channel (ENaC) inhibitor. P552-02 blocks ENaC function in humans, guinea pigs, rats and sheep, exhibits the characteristic of reduced dissociation rate after binding to ENaC, inhibits ENaC-mediated short-circuit current, and slows the absorption of airway surface liquid (ASL). P552-02 induces hyperkalemia in guinea pigs and rats, blocks the activity of airway ENaC in guinea pigs, and enhances mucociliary clearance in sheep both in vivo and in vitro. P552-02 is applicable to cystic fibrosis-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
P552-02 | P552-02 is an epithelial sodium channel (ENaC) inhibitor. P552-02 blocks ENaC function in humans, guinea pigs, rats and sheep, exhibits the characteristic of reduced dissociation rate after binding to ENaC, inhibits ENaC-mediated short-circuit current, and slows the absorption of airway surface liquid (ASL). P552-02 induces hyperkalemia in guinea pigs and rats, blocks the activity of airway ENaC in guinea pigs, and enhances mucociliary clearance in sheep both in vivo and in vitro. P552-02 is applicable to cystic fibrosis-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Coote KJ, et al. NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. British journal of pharmacology. 2015 Jun;172(11):2814-26. [Content Brief]
- [2]. Goralski JL, et al. Osmolytes and ion transport modulators: new strategies for airway surface rehydration. Current opinion in pharmacology. 2010 Jun;10(3):294-9.
